Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88-mutated (MYD88(MUT)) WM patients, but shows lower activity in MYD88 wild-type (MYD88(WT)) disease. MYD88(WT) patients a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Hunter, Zachary R., Xu, Lian, Tsakmaklis, Nickolas, Demos, Maria G., Kofides, Amanda, Jimenez, Cristina, Chan, Gloria G., Chen, Jiaji, Liu, Xia, Munshi, Manit, Gustine, Joshua, Meid, Kirsten, Patterson, Christopher J., Yang, Guang, Dubeau, Toni, Samur, Mehmet K., Castillo, Jorge J., Anderson, Kenneth C., Munshi, Nikhil C., Treon, Steven P.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2018
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234368/
https://ncbi.nlm.nih.gov/pubmed/30401751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022962
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires